Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Institute of Organ Transplantation, Zhejiang University, Hangzhou, China.
Liver Int. 2022 Aug;42(9):2110-2116. doi: 10.1111/liv.15288. Epub 2022 May 16.
Liver transplantation (LT) is the only effective method of treating end-stage liver disease, such as various types of liver failure. China has the largest number of patients with hepatitis B virus-related disease, which is also the main cause of liver failure. From the first LT performed in 1977, and especially over the past two decades, LT has experienced rapid development as a result of continuous research and innovation in China. China performs the second-highest number of LTs every year worldwide, and the quality of LT continues to improve. Starting January 1, 2015, all donor's livers have been from deceased donors and familial donors. Thus, China entered into a new era of LT. However, LT is still a challenging procedure in China. In this review, we introduced the brief history of LT in China, the epidemiology, aetiology and clinical outcomes of LT for liver failure in China and summarized the experience of LT from Chinese LT surgeons and scholars. The future perspectives of LT were also discussed, and it is expected that China's LT research could be further integrated elsewhere in the world.
肝移植（LT）是治疗终末期肝病（如各种类型的肝功能衰竭）的唯一有效方法。中国是乙型肝炎病毒相关疾病患者数量最多的国家，乙型肝炎病毒相关疾病也是肝功能衰竭的主要原因。自 1977 年进行首例 LT 以来，特别是在过去的二十年中，由于中国不断进行研究和创新，LT 得到了快速发展。中国每年进行的 LT 数量位居世界第二，LT 的质量也在不断提高。自 2015 年 1 月 1 日起，所有供体的肝脏均来自于已故供体和家族供体。因此，中国进入了 LT 的新时代。然而，LT 在中国仍然是一个具有挑战性的手术。在这篇综述中，我们介绍了 LT 在我国的简要历史，中国肝功能衰竭 LT 的流行病学、病因学和临床结果，并总结了中国 LT 外科医生和学者的 LT 经验。还讨论了 LT 的未来展望，预计中国的 LT 研究将在世界其他地方进一步整合。
